All about the vaxxHeres a quick look at the main vaccine brands being used in Vac2Normal and in the Kapamilya Vaccination Program: AstraZeneca, Moderna and Novavax’s Covovax.

OXFORD ASTRAZENECA

Manufacturer/developer: AstraZeneca, University of Oxford (UK)

Countries with EUA: 99 countries including US, UK, Australia, Mexico, Argentina, India, Philippines

Philippine FDA EUA approval: January 28, 2021

Age group covered by FDA EUA approval: 18 years old and above

Technology platform: Viral vector (nonreplicating)

Dose and frequency: 2 doses, 4-12 weeks apart

Vaccine efficacy (VE): 70.4% overall VE against symptomatic COVID-19, 14 days after the second dose

Common adverse events reported in Phase III clinical trials: Injection site pain and tenderness, fatigue, headache, feverishness, myalgia (muscle pain)

Serious adverse events reported in Phase III clinical trials: None reported

MODERNA

Manufacturer/developer: Moderna, National Institute of Allergy and Infectious Diseases (US)

Countries with EUA: 49 countries with EUA approval including US, UK, EU, Switzerland, Canada, Australia, Philippines

Philippine FDA EUA approval: May 5, 2021

Age group covered by FDA EUA approval: 18 years old and above

Technology platform: mRNA

Dose and frequency: 2 doses, 28 days apart

Vaccine efficacy (VE): 94.1% overall VE against symptomatic COVID-19, occurring at least 14 days after the second dose; 100% VE against severe COVID-19

Common adverse events reported in Phase III clinical trials: Injection site pain, fatigue, headache myalgia (muscle pain), arthralgia (joint pain), chills, nausea/vomiting, axillary swelling/tenderness, fever, swelling at the injection site and erythema (skin redness/inflammation) at the injection site

Serious adverse events reported in Phase III clinical trials: Severe allergic reactions, including anaphylaxis

COVOVAX

Manufacturer/developer: Serum Institute of India, Novavax (US)

Countries with EUA: No EUA approvals yet

Philippine FDA EUA approval: --

Age group covered by FDA EUA approval: --

Technology platform: Protein subunit

Dose and frequency: 2 doses, 21 days apart

Vaccine efficacy (VE): Awaiting EUA application

Common adverse events reported in Phase III clinical trials: Awaiting EUA application

Serious adverse events reported in Phase III clinical trials: Awaiting EUA application (Source: doh.gov.ph)